Axsome's AXS-12 reduces narcolepsy symptoms, positioning the company for success. Find out why AXSM stock is a buy with ...

A collection of common and new medications is showing good results against the constellation of symptoms that individualize ...

Once a controversial European depression treatment that never made it to the U.S. | The treatment, which was once a Pfizer ...

By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, e-commerce, Drug Stores and Others) & Region for 2024 to ...

The Phase III trial of AXS-12 showed results over placebo as the company looks towards a new drug application for its ...

Jenny Lee-Gilmore had trouble staying awake in school, vivid sleep hallucinations and would wake up six to 10 times per night ...

AXS-12 statistically significantly reduced the frequency of cataplexy attacks compared to placebo (p=0.017, primary endpoint) ...

Robert F. Kennedy Jr., recently chosen by Donald Trump as the country's health secretary, has been open about his experience ...

Eisai Inc. announced today its sponsorship of the upcoming webinar, "Lessons Learned from Central Disorders of Hypersomnolence and Future Directions", a key educational event from the Sleep Research ...

A three-decade series of coincidences will likely help doctors treat narcolepsy — and possibly prevent opioid addiction — and ...

Laryngeal dystonia (LD), a rare neurological disease that significantly impacts a person's ability to speak due to uncontrollable vocal cord spasms, can have a debilitating effect on a person's social ...

Her lab is also leading studies using artificial intelligence to determine which patients might benefit from the treatment, ...